US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.